COMPOUND DEEP DIVES · RESEARCH PROTOCOLS & STACKS
Conventional wisdom treats aging as a single process to be slowed — but the biology is more granular than that. The hallmarks of aging framework, first formalised by López-Otín et al. in 2013 and expanded in 2023, identifies at least twelve distinct, interconnected mechanisms driving biological deterioration: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, disabled macroautophagy, chronic inflammation, and dysbiosis.
Most longevity interventions target one or two of these nodes. The research question the Hallmarks Stack is built around is different: what happens when four compounds with orthogonal but partially overlapping mechanisms are considered together — each addressing a distinct cluster of hallmarks, but converging at shared signalling nodes?
NAD+, MOTS-c, Epithalon, and GHK-Cu have been studied across decades of preclinical literature — from mouse lifespan studies to in vitro gene-array work to cross-species RNA splicing analyses. Each has a distinct primary mechanism. Each also touches the AMPK/sirtuin axis, mitochondrial homeostasis, or genomic stability in ways that create potential convergence points.
This post maps that evidence base rigorously. Not to make efficacy claims, but to give the informed self-optimiser the mechanistic context to understand what these four research compounds are actually doing — and what the data cannot yet tell us.
The compounds in this stack have been studied individually across separate models, species, and research institutions. No peer-reviewed study to date has examined their co-administration. What follows is a synthesis of independent preclinical literatures, structured around the hallmarks framework.
NAD+ research spans C. elegans, mouse, and human models. The most mechanistically complete studies examine NAD+ depletion as a primary driver of aging across tissues, operating through at least four distinct axes: the SIRT1–7 deacetylase system, PARP-mediated DNA repair, mitophagy regulation via PINK1/Parkin and BNIP3L, and — in a 2026 cross-species study — RNA splicing fidelity via the EVA1C axis (Ai R & Fang EF, 2026, Autophagy, PMID: 41313318). The human NMN RCT by Yi L et al. (2023, GeroScience, PMID: 36482258) remains the most controlled human data point: 80 participants, double-blind, placebo-controlled, 60-day duration.
MOTS-c was first characterised in 2015 at USC Gerontology (Lee C et al., 2015, Cell Metabolism, PMID: 25738459) as a 16-amino-acid signalling molecule encoded by mitochondrial 12S rRNA. Subsequent mouse studies have explored its primary mechanism — the Folate-AICAR-AMPK pathway — and its role in nuclear stress response via antioxidant response element (ARE) binding. A 2023 review in Current Cardiology Reviews (Sivakumar R et al., 2026, PMID: 40574402) identified mechanistic overlap between MOTS-c and NAD+ at the AMPK/sirtuin signalling network.
Epithalon (tetrapeptide Ala-Glu-Asp-Gly) has been studied most extensively by Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. Key studies include in vitro fibroblast telomerase reactivation (Khavinson VKh et al., 2003, PMID: 12937682; 2004, PMID: 15455129) and the female SHR mouse lifespan study (Anisimov VN et al., 2003, Biogerontology, PMID: 14501183) using subcutaneous administration at ~30–40 µg/kg on 5 consecutive days per month from age 3 months to natural death.
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) research draws primarily from Pickart and Margolina’s gene-array analyses, demonstrating modulation of over 4,000 human genes in vitro (Pickart L & Margolina A, 2018, PMID: 29986520; Pickart L et al., 2014, PMID: 25302294), alongside formulation studies confirming bioactivity in delivery systems (Dymek M et al., 2023, PMID: 37896245).
NAD+ depletion is one of the most consistently replicated findings in aging biology. Concentrations decline across all tissues with age — driven by elevated CD38 hydrolase activity, competitive substrate drain from PARP enzymes during DNA repair, and reduced biosynthetic capacity. The downstream consequences are broad: all seven sirtuin deacetylases (SIRT1–7) are NAD+-dependent, meaning their activity tracks directly with available NAD+ substrate.
The canonical understanding places NAD+ upstream of SIRT1-mediated epigenetic remodelling, FOXO activation, and p53 regulation. The 2020 mechanistic review from the University of Oslo (Aman Y et al., PMID: 31812486) extended this to the mitophagy axis: NAD+ supplementation in mouse models restores PINK1/Parkin-mediated selective clearance of damaged mitochondria and BNIP3L-dependent receptor-mediated mitophagy, reducing the accumulation of dysfunctional mitochondria that drives reactive oxygen species (ROS) overproduction and senescence signalling.
The 2026 cross-species study by Ai & Fang (Autophagy, PMID: 41313318) adds a third, previously uncharacterised mechanism: NAD+ corrects hundreds of age- and Alzheimer’s-associated RNA splicing errors by restoring balanced expression of EVA1C isoforms, which in turn reinforces chaperone-assisted macroautophagy (via the BAG1/HSPA network) and proteasomal degradation of misfolded proteins including MAPT/tau. This positions NAD+ at a splice-switching level of aging biology that operates in parallel to, not instead of, its SIRT1 and PARP roles.
In the Yi et al. (2023) RCT, oral NMN at 300–900 mg/day dose-dependently elevated blood NAD+ concentrations versus placebo at both days 30 and 60 (p ≤ 0.001). Physical performance (6-minute walking test) improved significantly across all NMN-treated groups versus placebo (p < 0.01). Critically, biological age calculated via Aging.Ai 3.0 increased significantly in the placebo group by day 60 but remained unchanged in all NMN-treated groups — yielding a statistically significant between-group difference (p < 0.05). A 2024 Nature Metabolism study (Membrez M et al., PMID: 38504132) further validated NAD+ precursor strategies in aged male mouse muscle, demonstrating improved mitochondrial oxidative phosphorylation capacity and prevention of age-related strength decline via trigonelline supplementation acting through the same Preiss-Handler/SIRT pathway.
The ETH Zürich review (Sharma A et al., 2023, Nutrients, PMID: 36678315) maps the CD38/NAD+/SIRT1 axis as the mechanistic hub connecting NAD+ decline to metabolic dysfunction, neurodegeneration, genomic instability, and chronic inflammation — proposing co-administration with CD38 inhibitors or downstream sirtuin activators as a synergistic framework.
MOTS-c is not a conventional research compound — it is encoded by the mitochondrial genome itself, a 16-amino-acid open reading frame within the 12S rRNA gene. This alone makes it biologically unusual: the mitochondrial genome encodes only 37 genes in humans, and MOTS-c represents one of a small class of mitochondria-derived signalling molecules (MDPs) now recognised as having systemic regulatory function.
Its primary mechanism, as established by Lee et al. (2015, Cell Metabolism, PMID: 25738459), involves disruption of the intracellular folate cycle and de novo purine biosynthesis, leading to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) — a potent endogenous AMPK activator. AMPK activation then drives downstream improvements in skeletal muscle glucose uptake via GLUT4 upregulation, enhanced fatty acid oxidation, improved insulin sensitivity, and suppression of NF-κB-driven inflammatory signalling. In that discovery study, exogenous MOTS-c administration reversed diet-induced obesity and metabolic dysregulation in mouse models at pharmacological concentrations.
The 2023 mechanistic picture adds the nuclear signalling dimension. Under cellular stress and aging conditions, MOTS-c translocates from mitochondria to the nucleus, where it directly binds antioxidant response elements (AREs) — regulatory DNA sequences upstream of a broad array of stress-adaptation and antioxidant genes (Wan W et al., 2023, Journal of Translational Medicine, PMID: 36670507). This nuclear ARE binding is independent of the cytoplasmic AMPK pathway, suggesting MOTS-c operates through at least two distinct mechanisms simultaneously.
Critically, both MOTS-c and NAD+ converge on the AMPK/sirtuin signalling network. MOTS-c activates AMPK via the AICAR pathway; NAD+ activates sirtuins (which share substrate and regulatory linkage with AMPK via SIRT1-LKB1-AMPK crosstalk). This convergence at shared nodal points in the longevity signalling network is identified explicitly in the 2026 Sivakumar et al. cardiovascular aging review (PMID: 40574402), though direct co-administration data remains absent from the literature.
Serum MOTS-c levels decline consistently with age across species, and in the Gao et al. (2023, Metabolites, PMID: 36677050) analysis, MOTS-c modulation of STAT3 and IL-10 alongside GLUT4 upregulation positions it as a metabolic-immunological signalling molecule — relevant to inflammaging as well as metabolic function.
Telomere attrition is one of the most direct structural correlates of cellular aging. Most somatic cells are telomerase-negative — the hTERT catalytic subunit is silenced after embryonic development — meaning each cell division shortens the telomere cap until replicative senescence or crisis is reached (the Hayflick limit).
Epithalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from the pineal extract Epithalamin. The 2003 Khavinson study (Bulletin of Experimental Biology and Medicine, PMID: 12937682) demonstrated that adding Epithalon to telomerase-negative human fetal fibroblast cultures induced expression of the hTERT catalytic subunit, restoring enzymatic telomerase activity and producing measurable telomere elongation. This was the first reported reactivation of telomerase in normally telomerase-silent somatic cells by an exogenous small molecule.
The 2004 follow-up study (Khavinson VKh et al., PMID: 15455129) extended this finding to a functional lifespan endpoint: human diploid pulmonary fibroblasts approaching replicative senescence at passage 34 were treated with Epithalon, which restored telomere lengths to early-passage dimensions and enabled the cells to complete 10 additional divisions (reaching passage 44) beyond the Hayflick limit reached by untreated controls. The controls ceased division at passage 34.
At the organismal level, the Anisimov et al. (2003, Biogerontology, PMID: 14501183) SHR mouse lifespan study demonstrated that subcutaneous Epitalon (~30–40 µg/kg, 5 consecutive days/month, from age 3 months to natural death) increased maximum lifespan by 12.3% and last-decile survival by 13.3% (p < 0.01) in female mice. Bone marrow chromosome aberrations — a direct biomarker of genomic instability — were reduced by 17.1% versus saline controls (p < 0.05). Spontaneous leukemia incidence fell six-fold. The telomere and genomic stability mechanisms appear complementary rather than identical.
GHK-Cu occupies a structurally unique position in this stack. Where NAD+, MOTS-c, and Epithalon primarily address intracellular metabolic and nuclear mechanisms, GHK-Cu operates at the level of pan-genomic gene expression and extracellular matrix (ECM) homeostasis.
The Pickart & Margolina (2018, PMID: 29986520) gene-array analysis of GHK-Cu’s effects on human cell lines identified modulation of over 4,000 genes — broadly upregulating repair and regenerative programs (collagen and elastin synthesis, glycosaminoglycan production, angiogenesis, nerve outgrowth, proteasome activation, DNA repair genes, antioxidant systems, and TGF-β superfamily targets) while simultaneously downregulating pro-aging and pro-inflammatory programs (NF-κB signalling, fibrinogen synthesis genes, insulin/IGF cancer-growth axis, and COPD-associated tissue-destructive programs).
The 2014 analysis (Pickart L et al., PMID: 25302294) adds the endocrine dimension: plasma GHK concentrations decline from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 — a 60% reduction that coincides with the age-dependent shift toward inflammatory and degenerative gene expression profiles. This decline is not incidental; it mirrors what is observed with NAD+ and MOTS-c, suggesting a broader pattern of endogenous longevity signal depletion with age.
The Dymek et al. (2023, Pharmaceutics, PMID: 37896245) formulation study confirmed that GHK-Cu loaded into cationic liposomes (~100 nm) retained bioactivity and produced 48.9 ± 2.5% elastase inhibition in vitro — demonstrating active ECM protection against elastin degradation as a mechanism distinct from its gene-regulatory activity.
Table 1: Hallmarks Stack — Compound Mechanisms and Preclinical Evidence
| Compound | Study Type | Key Outcome | Citation |
|---|---|---|---|
| NAD+ (via NMN) | Human RCT, n=80, 60 days | Dose-dependent NAD+ elevation (p≤0.001); prevented biological age increase in treated groups vs. placebo (p<0.05) | Yi L et al., 2023, PMID: 36482258 |
| NAD+ | Mouse / C. elegans / human cells | Corrects age-associated RNA splicing errors via NAD+–EVA1C axis; reinforces chaperone autophagy and tau clearance | Ai R & Fang EF, 2026, PMID: 41313318 |
| NAD+ | Mouse mechanistic review | Restores PINK1/Parkin and BNIP3L mitophagy flux; reduces dysfunctional mitochondrial accumulation and senescence signalling | Aman Y et al., 2020, PMID: 31812486 |
| MOTS-c | Mouse, diet-induced obesity model | Prevented insulin resistance and diet-induced obesity via Folate-AICAR-AMPK pathway; upregulated GLUT4 in skeletal muscle | Lee C et al., 2015, PMID: 25738459 |
| MOTS-c | Mouse / mechanistic review | Nuclear ARE binding under stress; STAT3/IL-10 modulation; MOTS-c serum levels decline with age across species | Gao Y et al., 2023, PMID: 36677050 |
| Epithalon | In vitro human fibroblasts | Induced hTERT expression; restored telomerase activity; produced measurable telomere elongation in telomerase-negative somatic cells | Khavinson VKh et al., 2003, PMID: 12937682 |
| Epithalon | In vitro human fibroblasts | Restored telomere length; enabled 10 additional divisions beyond Hayflick limit (passage 34→44) vs. controls (stopped at 34) | Khavinson VKh et al., 2004, PMID: 15455129 |
| Epithalon (Epitalon) | Mouse lifespan, n=54/group | Maximum lifespan +12.3%, last-decile survival +13.3% (p<0.01); chromosome aberrations −17.1% (p<0.05); leukemia incidence 6-fold lower | Anisimov VN et al., 2003, PMID: 14501183 |
| GHK-Cu | In vitro gene array | Modulates >4,000 human genes; upregulates DNA repair, proteasome, TGF-β, antioxidants; downregulates NF-κB, fibrinogen, IGF oncogenic axis | Pickart L & Margolina A, 2018, PMID: 29986520 |
| GHK-Cu | In vitro liposome formulation | 48.9 ± 2.5% elastase inhibition; confirmed bioactivity across delivery formats | Dymek M et al., 2023, PMID: 37896245 |
Table 2: Signalling Pathway Convergence Across Stack Compounds
| Pathway / Hallmark | NAD+ | MOTS-c | Epithalon | GHK-Cu |
|---|---|---|---|---|
| AMPK activation | Indirect (SIRT1-LKB1 crosstalk) | Direct (AICAR accumulation) | Not established | Not established |
| Sirtuin (SIRT1–7) activation | Primary (rate-limiting substrate) | Indirect (via AMPK) | Not established | Not established |
| Mitochondrial homeostasis / mitophagy | Direct (PINK1/Parkin, BNIP3L) | Direct (source; retrograde signalling) | Not established | Not established |
| Genomic stability / DNA repair | PARP-mediated repair (substrate) | Not established | Chromosome aberration reduction (in vivo) | Gene-array upregulation of DNA repair genes |
| Telomere biology | Not established | Not established | hTERT induction; telomere elongation | Not established |
| NF-κB / inflammaging | SIRT1-mediated suppression | AMPK/STAT3 modulation | Not established | Direct gene-level downregulation |
| Proteostasis / autophagy | RNA splicing + chaperone network (EVA1C axis) | Not established | Not established | Proteasome gene activation |
| ECM / structural repair | Not established | Not established | Not established | Collagen, elastin, GAG synthesis |
| Endogenous age-related decline | Yes (tissue-wide) | Yes (serum decline with age) | Not directly measured | Yes (plasma ~200→80 ng/mL, age 20→60) |
The mechanistic case for this combination is genuinely interesting — and deserves a rigorous accounting of what the evidence cannot yet support.
The most fundamental limitation is this: NAD+, MOTS-c, Epithalon, and GHK-Cu have never been studied together. The convergence at AMPK/sirtuin nodes identified in Table 2 is inferred from independent preclinical literatures, not measured in co-administration models. Whether this convergence produces additive effects, synergistic effects, or — in any pathway — antagonistic interference is entirely unknown. As the ETH Zürich review notes (Sharma A et al., 2023, PMID: 36678315), the framework for synergistic NAD+ stacking is theoretically sound, but “theoretically sound” and “empirically demonstrated” are different categories. Anyone claiming this stack has proven synergistic effects is working beyond the data.
The Epithalon/Epitalon literature — including both landmark in vitro studies and the mouse lifespan data — originates almost entirely from a single institution: the St. Petersburg Institute of Bioregulation and Gerontology, under the leadership of V.Kh. Khavinson. This is not a dismissal of the work; the mechanistic findings are biologically coherent and the in vitro telomerase data is internally consistent. But independent replication by Western research groups is limited, and no large-scale RCT has evaluated Epithalon against human longevity endpoints. The 12.3% maximum lifespan extension in SHR mice (n=54/group) is compelling, but was observed in a single inbred mouse strain under specific housing conditions — cross-species translation cannot be assumed.
All human evidence for MOTS-c is cross-sectional and correlational: studies observe that serum MOTS-c levels decline with age and positively associate with metabolic health and exercise phenotype. No randomised controlled trial has evaluated exogenous MOTS-c administration in humans for any endpoint — longevity, metabolic, or otherwise. The mouse data (Lee et al., 2015) used pharmacological doses that may not directly translate to equivalent effective concentrations in humans, given metabolic scaling differences and the species-specific biology of mitochondrial-derived signalling. The MOTS-c/NAD+ convergence at AMPK/sirtuin nodes identified by Sivakumar et al. (2026, PMID: 40574402) is mechanistically plausible — but plausibility is a hypothesis generator, not a conclusion.
The striking 4,000-gene modulation finding (Pickart & Margolina, 2018) was generated in in vitro cell line assays. Whether systemic or topical GHK-Cu exposure achieves the tissue concentrations necessary to replicate this genomic shift in vivo — in an intact organism, with normal plasma clearance, protein binding, and tissue distribution — has not been established in controlled human studies. The plasma decline from 200 to 80 ng/mL between ages 20 and 60 is a correlative observation, not a demonstration of causality; it does not confirm that exogenous GHK-Cu supplementation reverses the associated gene expression changes at physiologically achievable concentrations.
Epithalon (a tetrapeptide) and GHK-Cu (a tripeptide-copper complex) are subject to gastrointestinal proteolysis when administered orally. While short signalling molecules can demonstrate partial oral bioavailability — some studies suggest GHK survives gastric transit in partial form — no pharmacokinetic studies with oral dosing have been published for these specific compounds in longevity research contexts. NAD+ precursors (NMN/NR) have demonstrated oral bioavailability with blood-level confirmation (Yi et al., 2023). MOTS-c oral bioavailability data is similarly limited. The stability and formulation questions are real, and our research notes address the oral bioavailability literature in the context of bioregulator delivery science.
The most robust human data point in this literature — the Yi et al. (2023) NMN RCT — measured blood NAD+ levels, 6-minute walking distance, and a biological age algorithm output. These are surrogate endpoints. The 80-participant trial ran for 60 days. No study in this literature has followed a cohort to hard longevity, morbidity, or all-cause mortality endpoints in humans. This gap matters enormously when interpreting preclinical lifespan findings.
Four research compounds. Four distinct primary mechanisms. Multiple convergence points in the longevity signalling network. That is an accurate summary of where the preclinical literature stands with the Hallmarks Stack.
NAD+ addresses the metabolic-transcriptional foundation: sirtuin substrate, PARP cofactor, mitophagy regulator, and — per 2026 data — splice-switching corrector. MOTS-c extends the mitochondrial communication layer, activating AMPK via the Folate-AICAR axis and providing nuclear stress response via ARE binding. Epithalon targets the structural biology of cellular lifespan — hTERT reactivation, telomere elongation, and in vivo genomic stability — in models that no other compound in this stack addresses. GHK-Cu completes the picture at the genome-wide level, resetting gene expression toward repair and regeneration while providing direct ECM protection through elastase inhibition and structural protein synthesis.
What the data cannot yet tell us: whether these four compounds interact beneficially when co-administered, what oral bioavailability profiles look like in controlled pharmacokinetic studies, or how preclinical findings translate to human longevity endpoints beyond surrogate markers. Those are honest limitations, and they matter.
For researchers exploring the longevity stack literature, this combination represents one of the more mechanistically coherent multi-target research protocols currently available. The individual compound evidence — particularly for NAD+ and Epithalon — is deeper than most. The stack-level science is genuinely the next research frontier.
Browse the full research compound catalogue and explore the broader longevity compounds category for additional context on individual compound profiles. For comparative stack design context, see also the Longevity Stack (Epithalon, GHK-Cu, NAD+) and the Khavinson Triple (Epithalon, Pinealon, Semax). Additional mechanistic context on cognitive and metabolic compounds is available via our research notes.
This post was researched and written by the biohacker.team editorial and research staff. All compounds referenced in the Hallmarks Stack — NAD+, MOTS-c, Epithalon, and GHK-Cu — are sourced to research-grade specification and subject to third-party HPLC purity verification and certificate of analysis (COA) testing prior to release. We publish COA documentation for each batch. Our sourcing standards, testing protocols, and full research transparency policy are available at biohacker.team/about/. These compounds are provided strictly as research materials and are sold to researchers operating within applicable regulatory frameworks.
For research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.